WEBINAR: Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay – 28 June 2023

cnb825 webinar promo v1 |
Learn more
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • ISSX DMDG 2023

      • MPS World Summit Berlin 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

July 19, 2022 by CN Bio

State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services

Cambridge, UK, 19 July 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services. The Company’s laboratory space has been doubled in response to the increasing market demand for OOC services as the technology gains traction within drug discovery and development programmes.

CN Bio’s contract research services harness the Company’s next-generation MPS technology, a decade of expertise and proven-track record across a growing portfolio of applications including: drug metabolism, safety toxicology, oncology and Non-Alcoholic Steatohepatitis (NASH). Generating actionable data for its customers within weeks, the team collaborate with researchers to create an experimental design that delivers unique human-translatable insights, whilst saving significant time and cost versus animal studies.

The rising demand for services demonstrates acceptance of OOC data by pharma and biotech companies in their therapeutic programs. This is being fuelled by repeat business, growing interest from regulatory agencies, the technologies ability to predict clinical outcomes and its potential to replace animal models – especially for the testing of new drug modalities with human-specific modes of action. As the body of evidence demonstrating OOC’s superior performance versus traditional approaches increases, the Company’s expansion ensures it is ready to meet the needs of this growing market.


Dr Gareth Guenigault, Lead Scientist of CN Bio’s Contract Research Services, said: “This expansion is an exciting next step in the progression of our contract research services offering. As we see increasing awareness within the drug discovery, development and regulatory fields that animal models don’t always get it right, nor are ethically desirable, we are poised to offer solutions that fit researchers’ individual needs. By utilising the power of OOC technology to provide early stage, clinically translatable data across a range of applications, we hope to give customers greater confidence in the success of their projects, in a fraction of the time and cost.”


thumbnail 20220708 141204 1 |

Category iconPress releases

Primary Sidebar

Other recent news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023
  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility | Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

ISSX DMDG 2023 June 11-14, 2023

MPS World Summit Berlin 2023 June 26-30, 2023